Latest $2.5M renewal continues NCI grant for 17 years

Waltz says, since receiving initial funding in 2008, the T32 has supported 42 trainees—10 predoctoral fellows and 32 postdoctoral fellows—and that over 150 papers have been published by trainees as a result of the support. This renewal will support up to eight additional trainees annually.

"As a result of the T32 funding, trainees are provided salary support as well as a number of workshops, career activities and courses to complement their research experiences and to make them more competent and competitive cancer biologists,” she adds. "As part of the training program, the trainees also apply for their own external funding. In doing so, 16 extramural grants have been obtained by the trainees including prestigious fellowships from the National Institutes of Health, American Cancer Society, Department of Defense and the American Heart Association. Not only does the training grant provide resources to support trainees but also provides the training to catapult the trainees to early career success in garnering their own funding—and multiplying the extramural research dollars to the university.” 

Price adds that a number of past trainees have obtained leadership positions in academia and industry.  

"This training serves as an important springboard for young scientists to secure funding and professional cancer research positions,” she adds. 

Each cancer therapeutics program trainee is partnered with a scientific and clinical faculty mentor to facilitate collaboration in a defined interest area related to cancer biology.  Applications to the program are accepted and evaluated on an ongoing basis. More information is available at cancerbiology.uc.edu or by contacting Waltz at susan.waltz@uc.edu.